How will national regulators in Europe impose fines for missing clinical trial results?

In late 2021, national medicines regulators will get clear legal powers to impose fines and other sanctions on European companies and institutions that fail to make the results of their drug trials public.

We are happy to share this blog post in which TranspariMED's legal analyst Muhammad Dwistaraifa Rasendriya explains the legal context and how the process will work.

If you know of other news stories of potentially high interest to EMWA members, please drop us an email with the details.